Background: The sodium glucose cotransporter-2 (SGLT2) inhibitors are a novel group of
drugs for treatment of type 2 diabetes mellitus. We investigated whether there is a dose …

Sodium–glucose cotransporter 2 (SGLT2) inhibitors are a fairly new class of treatment for
diabetes mellitus. Some data suggest SGLT2 inhibitors are associated with a risk of severe …

Previous trial evidence suggested potential risk of serious urinary tract infections (UTIs) and
genital infections in type 2 diabetes patients using sodium glucose co-transporter-2 …

Aims There is concern about the infection-related safety profile of sodium–glucose co-
transporter 2 (SGLT-2) inhibitors. We aimed to determine the effect of SGLT-2 inhibitors on …

Abstract Sodium-glucose cotransporter 2 (SGLT2) inhibitors have revolutionized our
armamentarium for kidney and heart protection in patients with or without diabetes. Based …

SUMMARY Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are drugs that act by
maintaining glycosuria. Recent studies have shown promising effects of these in the …

Aims To evaluate the effects of different sodium‐glucose co‐transporter 2 (SGLT2) inhibitors
on the risk of urinary tract infections (UTIs) and genital infections in patients with type 2 …

Abstract Sodium–glucose co-transporter-2 (SGLT2) inhibitors improve cardiovascular and
renal outcomes in patients with type 2 diabetes, including those with diabetic kidney …

Abstract Objectives Sodium-glucose cotransporter-2 (SGLT2) inhibitor–induced glycosuria is
hypothesized to increase the risk of urinary tract infections (UTIs). We assessed the risk of …

Abstract Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a novel class of antidiabetic
drugs. Guidelines for the proper use of SGLT2 inhibitors recommend caution regarding …